INCIDENCE AND RISK FACTORS OF INTRAOCULAR INFLAMMATION AFTER BROLUCIZUMAB TREATMENT IN JAPAN : A Multicenter Age-Related Macular Degeneration Study
PURPOSE: To investigate the incidence of intraocular inflammation (IOI) and its risk factors following intravitreal injections of brolucizumab for neovascular age-related macular degeneration in Japan.
METHODS: A total of 1,351 Japanese consecutive patients with neovascular age-related macular degeneration who were treated with brolucizumab from May 2020 to May 2022 at 14 institutions were examined. The variables analyzed were the number of brolucizumab injections, time to onset of IOI, and risk factors.
RESULTS: Intraocular inflammation developed in 152 eyes (11.3%). Retinal vasculitis and/or retinal occlusion occurred in 53 eyes (3.9%). Ninety-four patients received bilaterally, bilateral IOI occurred in five patients (5.3%). Sixteen eyes (1.2%) had irreversible visual acuity loss and nine eyes (0.67%) had visual loss of three lines or more due to retinal vasculitis and/or retinal occlusion. The cumulative IOI incidence was 4.5%, 10.3%, and 12.2% at 30, 180, and 365 days (1-year), respectively. History of IOI (including retinal vasculitis) and/or retinal occlusion (odds ratio [OR], 5.41; P = 0.0075) and female sex (OR, 1.99; P = 0.0004) were significantly associated with IOI onset.
CONCLUSION: The 1-year cumulative incidence of IOI in Japanese neovascular age-related macular degeneration patients treated with brolucizumab was 12.2%. History of IOI (including retinal vasculitis) and/or retinal occlusion and female sex were significant risk factors.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:44 |
|---|---|
| Enthalten in: |
Retina (Philadelphia, Pa.) - 44(2024), 4 vom: 01. Apr., Seite 714-722 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Inoda, Satoru [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Angiogenesis Inhibitors |
|---|
| Anmerkungen: |
Date Completed 28.03.2024 Date Revised 05.04.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1097/IAE.0000000000004009 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365072656 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365072656 | ||
| 003 | DE-627 | ||
| 005 | 20240405233239.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/IAE.0000000000004009 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1366.xml |
| 035 | |a (DE-627)NLM365072656 | ||
| 035 | |a (NLM)38016089 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Inoda, Satoru |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a INCIDENCE AND RISK FACTORS OF INTRAOCULAR INFLAMMATION AFTER BROLUCIZUMAB TREATMENT IN JAPAN |b A Multicenter Age-Related Macular Degeneration Study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.03.2024 | ||
| 500 | |a Date Revised 05.04.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a PURPOSE: To investigate the incidence of intraocular inflammation (IOI) and its risk factors following intravitreal injections of brolucizumab for neovascular age-related macular degeneration in Japan | ||
| 520 | |a METHODS: A total of 1,351 Japanese consecutive patients with neovascular age-related macular degeneration who were treated with brolucizumab from May 2020 to May 2022 at 14 institutions were examined. The variables analyzed were the number of brolucizumab injections, time to onset of IOI, and risk factors | ||
| 520 | |a RESULTS: Intraocular inflammation developed in 152 eyes (11.3%). Retinal vasculitis and/or retinal occlusion occurred in 53 eyes (3.9%). Ninety-four patients received bilaterally, bilateral IOI occurred in five patients (5.3%). Sixteen eyes (1.2%) had irreversible visual acuity loss and nine eyes (0.67%) had visual loss of three lines or more due to retinal vasculitis and/or retinal occlusion. The cumulative IOI incidence was 4.5%, 10.3%, and 12.2% at 30, 180, and 365 days (1-year), respectively. History of IOI (including retinal vasculitis) and/or retinal occlusion (odds ratio [OR], 5.41; P = 0.0075) and female sex (OR, 1.99; P = 0.0004) were significantly associated with IOI onset | ||
| 520 | |a CONCLUSION: The 1-year cumulative incidence of IOI in Japanese neovascular age-related macular degeneration patients treated with brolucizumab was 12.2%. History of IOI (including retinal vasculitis) and/or retinal occlusion and female sex were significant risk factors | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Angiogenesis Inhibitors |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a brolucizumab |2 NLM | |
| 650 | 7 | |a XSZ53G39H5 |2 NLM | |
| 700 | 1 | |a Takahashi, Hidenori |e verfasserin |4 aut | |
| 700 | 1 | |a Maruyama-Inoue, Maiko |e verfasserin |4 aut | |
| 700 | 1 | |a Ikeda, Shoko |e verfasserin |4 aut | |
| 700 | 1 | |a Sekiryu, Tetsuju |e verfasserin |4 aut | |
| 700 | 1 | |a Itagaki, Kanako |e verfasserin |4 aut | |
| 700 | 1 | |a Matsumoto, Hidetaka |e verfasserin |4 aut | |
| 700 | 1 | |a Mukai, Ryo |e verfasserin |4 aut | |
| 700 | 1 | |a Nagai, Yoshimi |e verfasserin |4 aut | |
| 700 | 1 | |a Ohnaka, Masayuki |e verfasserin |4 aut | |
| 700 | 1 | |a Kusuhara, Sentaro |e verfasserin |4 aut | |
| 700 | 1 | |a Miki, Akiko |e verfasserin |4 aut | |
| 700 | 1 | |a Okada, Annabelle A |e verfasserin |4 aut | |
| 700 | 1 | |a Nakayama, Makiko |e verfasserin |4 aut | |
| 700 | 1 | |a Nishiguchi, Koji M |e verfasserin |4 aut | |
| 700 | 1 | |a Takeuchi, Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Mori, Ryusaburo |e verfasserin |4 aut | |
| 700 | 1 | |a Tanaka, Koji |e verfasserin |4 aut | |
| 700 | 1 | |a Honda, Shigeru |e verfasserin |4 aut | |
| 700 | 1 | |a Kohno, Takeya |e verfasserin |4 aut | |
| 700 | 1 | |a Koizumi, Hideki |e verfasserin |4 aut | |
| 700 | 1 | |a Miyara, Yasunori |e verfasserin |4 aut | |
| 700 | 1 | |a Inoue, Yuji |e verfasserin |4 aut | |
| 700 | 1 | |a Takana, Hiroki |e verfasserin |4 aut | |
| 700 | 1 | |a Iida, Tomohiro |e verfasserin |4 aut | |
| 700 | 1 | |a Maruko, Ichiro |e verfasserin |4 aut | |
| 700 | 1 | |a Hayashi, Atsushi |e verfasserin |4 aut | |
| 700 | 1 | |a Ueda-Consolvo, Tomoko |e verfasserin |4 aut | |
| 700 | 1 | |a Yanagi, Yasuo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Retina (Philadelphia, Pa.) |d 1981 |g 44(2024), 4 vom: 01. Apr., Seite 714-722 |w (DE-627)NLM012598550 |x 1539-2864 |7 nnns |
| 773 | 1 | 8 | |g volume:44 |g year:2024 |g number:4 |g day:01 |g month:04 |g pages:714-722 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/IAE.0000000000004009 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 44 |j 2024 |e 4 |b 01 |c 04 |h 714-722 | ||